Abstract
The rapid expansion of radiopharmaceutical therapy, fueled by new radiopharmaceuticals approved by the Food and Drug Administration and novel theranostic approaches, has created an urgent demand for advanced training beyond foundational nuclear medicine education. To address this gap, the University of Alabama at Birmingham and the Society of Nuclear Medicine and Molecular Imaging launched the Nuclear Medicine Therapy Intensive in 2024. Designed for practicing nuclear medicine technologists and nuclear medicine advanced associates, this program integrates didactic instruction, simulation-based learning, interprofessional collaboration, and innovative capstone experiences (e.g., a nuclear medicine therapy escape room). Participants engage in activities that strengthen their knowledge in radiation safety, dosimetry, patient eligibility, communication, and clinical trial literacy while applying skills in hands-on therapy simulations. Preassessment and postassessment results from 2024 and 2025 cohorts demonstrated marked gains in knowledge and confidence, with most graduates directly working with theranostics services at their institutions. The weeklong intensive serves as a model for preparing professionals to deliver radiopharmaceutical therapies safely and effectively and with patient-centered excellence.